Next 10 |
home / stock / mdna:cc / mdna:cc news
ASCO has informed the Company that the previously accepted MDNA11 oral abstract has been withdrawn due to alleged violation of their prior publication policy based solely on their review of the abstract presented at AACR 2024. Medicenna disagrees with ASCO’s decision as the AACR ...
Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 30, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA) (MDNAF: OTCQB), a cli...
A look at the top 10 most actives in Canada Adventus Mining Corporation (ADZN) rose 7.1% to $0.45 on volume of 4,771,403 shares Guanajuato Silver Company Ltd. (GSVR) fell 15.1% to $0.1825 on volume of 3,755,313 shares BetaPro Natural Gas Leveraged Daily Bull ETF (HNU) fell 2.2% to $3.315 ...
Canadian Investment Regulatory Organization Trade Resumption - MDNA Canada NewsWire TORONTO , April 26, 2024 /CNW/ - Trading resumes in: Company: Medicenna Therapeutics Corp. TSX Symbol: MDNA All Issues: Yes Resumption (ET): 8:30 AM CIRO can m...
Canadian Investment Regulatory Organization Trading Halt - MDNA Canada NewsWire TORONTO , April 26, 2024 /CNW/ - The following issues have been halted by CIRO: Company: Medicenna Therapeutics Corp. TSX Symbol: MDNA All Issues: Yes Reason: Pending News...
Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA) (MDNAF: OTCQB), a c...
Oral presentation of MDNA11’s Phase 1/2 ABILITY-1 Study will feature new and updated clinical data Updated bizaxofusp survival results from the Phase 2b recurrent glioblastoma trial versus propensity matched external control arm will also be presented as a poster TORONTO an...
100% reduction of target lesions in one melanoma and one pancreatic cancer patient observed among 4 Partial Responses (PR) to date which include 2 of 4 evaluable dose expansion patients and 2 of 2 MSI-H patients Durable stable disease (SD) in 3 melanoma patients for 6 to 18 months with co...
MDNA113 is targeted to the tumor site where it is activated to simultaneously deliver two immunotherapies, an IL-2 superkine and anti-PD1 antibody, to the same cancer fighting immune cells in the tumor micro-environment (TME) to maximize efficacy and minimize systemic toxicity MDNA113 is ...
TORONTO and HOUSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that Dr. Fahar Merc...
News, Short Squeeze, Breakout and More Instantly...
Medicenna Therapeutics Corp. Company Name:
MDNA:CC Stock Symbol:
TSXC Market:
ASCO has informed the Company that the previously accepted MDNA11 oral abstract has been withdrawn due to alleged violation of their prior publication policy based solely on their review of the abstract presented at AACR 2024. Medicenna disagrees with ASCO’s decision as the AACR ...
Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 30, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA) (MDNAF: OTCQB), a cli...
A look at the top 10 most actives in Canada Adventus Mining Corporation (ADZN) rose 7.1% to $0.45 on volume of 4,771,403 shares Guanajuato Silver Company Ltd. (GSVR) fell 15.1% to $0.1825 on volume of 3,755,313 shares BetaPro Natural Gas Leveraged Daily Bull ETF (HNU) fell 2.2% to $3.315 ...